艾曲泊帕联合环孢素A治疗输血依赖非重型再生障碍性贫血疗效分析  

The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia:a retrospective study from single center

作　　者：陈妤 查蔷 黄菲[1] 乔纯[1] 王琰[1] 王蓉[1] 李建勇[1] 沈文怡[1] Chen Yu;Zha Qiang;Huang Fei;Qiao Chun;Wang Yan;Wang Rong;Li Jianyong;Shen Wenyi(Department of Hematology,First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院,江苏省人民医院血液科,南京210029

出　　处：《中华内科杂志》2022年第4期409-411,共3页Chinese Journal of Internal Medicine

基　　金：江苏省卫计委项目(Z201402);科教强卫工程医学青年人才(QNRC2016565);江苏省六大人才高峰(WSN-026)。

摘　　要：回顾性分析2019年至2021年于江苏省人民医院血液科接受艾曲泊帕联合环孢素A(CsA)的13例初治输血依赖非重型再生障碍性贫血(transfusion-dependent non-severe aplastic anemia,TD-NSAA)患者的临床资料,评估艾曲泊帕联合CsA治疗TD-NSAA的疗效、不良反应等。13例TD-NSAA患者治疗3个月总体血液学反应(OR)12/13。至随访截点,12例患者获得治疗反应,其中2例达完全血液学反应(CR),9例达部分血液学反应(PR),1例达血液学反应(HR)。1例患者在艾曲泊帕治疗6个月时转为阵发性睡眠性血红蛋白尿。5例患者治疗期间出现不同程度的不良反应,但未对治疗造成影响。对比既往单一CsA方案疗效,对于TD-NSAA,艾曲泊帕联合CsA应用可提高疗效且安全性较好。The main purpose of our study was to evaluate the efficacy and safety of eltrombopag plus cyclosporine A(CsA)in transfusion-dependent non-severe aplastic anemia(TD-NSAA).The clinical characteristics of 13 TD-NSAA patients who received initial treatment of eltrombopag plus CsA from 2019 to 2021 were retrospectively analyzed.The 3-month overall hematological response(OR)rate was 12/13.Until the end of follow-up,12 patients responded,among whom 2 patients reached complete response(CR)and 9 patients reached partial response(PR)and 1 with HR.Paroxysmal nocturnal hemoglobinuria(PNH)developed in one patient at 6 months after treatment.Five of thirteen patients reported mild adverse reactions,which were all manageable.Compared with historical data,the combination of eltrombopag with CsA is an effective regimen in patients with TD-NSAA.

关 键 词：艾曲泊帕 输血依赖非重型再生障碍性贫血 环孢素A 治疗反应 

分 类 号：R556.5[医药卫生—血液循环系统疾病]